Vericel earned FDA approval for a supplemental Biologics License Application, which will expand the company's Maci label to include arthroscopy, according to an Aug. 26 news release.
The expanded label approves Maci in knee arthroscopy to repair symptomatic single or multiple full-thickness cartilage defects up to 4 cm. Maci Arthro is a less invasive technique compared to the standard approach and lets surgeons deliver the implant through small incisions.
Maci is a cellularized scaffold that uses tissue engineering processes to grow cells using cartilage tissue from the patient's own knee. It is the only restorative biologic cartilage repair approved for arthroscopic administration.